76
|
Bossi I, D'Anna M, Vaccaro V, Caria MP, Colombo P, De Marco F, Oreglia J, Piccalò G, Piccaluga E, Soriano F, Oliva F, Klugmann S. [Paclitaxel-coated balloons for in-stent restenosis treatment: long-term clinical results and predictors of recurrent target lesion revascularization]. GIORNALE ITALIANO DI CARDIOLOGIA (2006) 2018; 19:232-238. [PMID: 29912237 DOI: 10.1714/2898.29217] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND The aim of this study was to report clinical outcomes in patients treated with paclitaxel-coated balloons (PCB) for in-stent restenosis (ISR) in both bare metal (BMS) and drug-eluting stent (DES). METHODS Between May 2009 and December 2015, we treated 155 ISR in 140 patients. At recruitment, 35% of patients had diabetes. Among the lesions, 125 were first occurrence (55 within BMS and 70 within DES) and 30 recurrent; 24 ISR were multi-metal layered. Mean reference diameter was 2.79 ± 0.52 mm and mean lesion length 13.2 ± 7.1 mm. PCB use included 32 Dior I, 97 InPact Falcon, 18 Panthera Lux, and 8 Restore DEB. RESULTS At a median follow-up of 442 days, we observed 18 target lesion revascularizations (TLR), one myocardial infarction, 3 cardiac deaths, and 5 non-cardiac deaths. TLR occurrence differed according to type of ISR (4% within BMS, 14% within DES, 28% within recurrent ISR; p<0.05). TLR was associated with PCB type (35% Dior I, 9% InPact Falcon, 0% Panthera Lux and Restore DEB; p<0.05). Multivariable analysis revealed that first-generation PCB without a carrier (hazard ratio [HR] 2.50, 95% confidence interval [CI] 0.96-6.50; p=0.06) and recurrent ISR (HR 7.76, 95% CI 1.56-38.66; p=0.01) correlated with subsequent TLR. CONCLUSIONS Our results confirm the safety and efficacy of PCB for ISR treatment both within BMS and DES. PCB type and recurrent ISR correlate with subsequent TLR.
Collapse
|
77
|
Axelrad J, Pinsino A, Thanataveerat A, Cagliostro B, Flannery M, Ross K, Te-Frey R, Effner L, Garan A, Topkara V, Takayama H, Takeda K, Naka Y, Colombo P, Gonda T, Yuzefpolskaya M. A Prospective Validation of the First Endoscopic Management Algorithm for Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
78
|
Breslin N, Salerno D, Restaino S, Latif F, Takeda K, Takayama H, Farr M, Colombo P, Jennings D. Pre-transplant Amiodarone Reduces Weight-based Tacrolimus Dosing Requirements in Heart Transplant Recipients. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
79
|
Lange N, Baker W, Shullo M, Latif F, Restaino S, Takeda K, Takayama H, Naka Y, Farr M, Colombo P, Jennings D. Outcomes Associated With Mammalian Target of Rapamycin (mTOR) Inhibitors in Heart Transplant Recipients: A Meta-analysis. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
80
|
Colombo P, Pallazzi G, Perna L, Broggi S, Cattaneo G, Fiorino C, Mangili P, Parisi R, Calandrino R. EP-1785: Impact of CT artifacts of planar phantoms on VMAT pre-clinical dosimetry using the Acuros algorithm. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32094-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
81
|
Bonini M, Šikoparija B, Skjøth CA, Cislaghi G, Colombo P, Testoni C, Smith M. Ambrosia pollen source inventory for Italy: a multi-purpose tool to assess the impact of the ragweed leaf beetle (Ophraella communa LeSage) on populations of its host plant. INTERNATIONAL JOURNAL OF BIOMETEOROLOGY 2018; 62:597-608. [PMID: 29159703 DOI: 10.1007/s00484-017-1469-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2017] [Revised: 10/16/2017] [Accepted: 10/28/2017] [Indexed: 06/07/2023]
Abstract
Here, we produce Ambrosia pollen source inventories for Italy that focuses on the periods before and after the accidental introduction of the Ophraella communa beetle. The inventory uses the top-down approach that combines the annual Ambrosia pollen index from a number of monitoring stations in the source region as well as Ambrosia ecology, local knowledge of Ambrosia infestation and detailed land cover information. The final inventory is gridded to a 5 × 5-km resolution using a stereographic projection. The sites with the highest European Infection levels were recorded in the north of Italy at Busto Arsizio (VA3) (European Infection level 2003-2014 = 52.1) and Magenta (MI7) (European Infection level 2003-2014 = 51.3), whereas the sites with the lowest (i.e. around 0.0) were generally located to the south of the country. Analysis showed that the European Infection level in all of Italy was significantly lower in 2013-2014 compared to 2003-2012, and this decrease was even more pronounced at the sites in the area where Ophraella communa was distributed. Cross-validations show that the sensitivity to the inclusion of stations is typically below 1% (for two thirds of the stations) and that the station Magenta (MI7) had the largest impact compared to all other stations. This is the first time that pollen source inventories from different temporal periods have been compared in this way and has implications for simulating interannual variations in pollen emission as well as evaluating the management of anemophilous plants like Ambrosia artemisiifolia.
Collapse
|
82
|
Cevasco M, Ikegami H, Willey J, Garan A, Chan C, Han J, Colombo P, Yusefpolskaya M, Kurlansky P, Naka Y, Takayama H, Takeda K. VA-ECMO Cannulation Strategy and Influence on Cerebral Blood Flow Velocities. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
83
|
Perale G, Giordano C, Daniele F, Tunesi M, Colombo P, Gottardo L, Maccagnan S, Masi M. Extruded Ceramic Microelectrodes for Biomedical Applications. Int J Artif Organs 2018; 31:272-8. [DOI: 10.1177/039139880803100312] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A new process, based on the micro-co-extrusion of preceramic precursors, has been studied for manufacturing ceramic microelectrodes to be used in biomedical applications. Commercially available silicon polymers were applied and proper doping resulted in electrically conductive ceramic filaments. Chemical reticulation and high-temperature pyrolysis were applied to convert the polymeric resins into Si-O-C ceramic materials. Circular microelectrodes were manufactured with diameters between 100 μm and 5 mm with a different number of inner conductive lines (from 1 to 80). The flexural strength of the filaments depended on the outer diameter size; doping with carbon black produced filaments with an average conductivity of approximately 0.4 S/cm for a 50% weight carbon black load. The results achieved by in vitro studies confirmed a good biological performance of Si-O-C ceramic structures with both hard and soft tissue cell models.
Collapse
|
84
|
Caccavo D, Barba A, d'Amore M, De Piano R, Lamberti G, Rossi A, Colombo P. Modeling the modified drug release from curved shape drug delivery systems – Dome Matrix®. Eur J Pharm Biopharm 2017; 121:24-31. [DOI: 10.1016/j.ejpb.2017.08.016] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Revised: 08/23/2017] [Accepted: 08/25/2017] [Indexed: 01/01/2023]
|
85
|
Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S, Lettieri C, Bossi I, Colombo P, Rigattieri S, Dossena C, Anzuini A, Capodanno D, Senni M, Angiolillo DJ. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circ Cardiovasc Interv 2017; 10:CIRCINTERVENTIONS.116.004368. [PMID: 28193678 DOI: 10.1161/circinterventions.116.004368] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Accepted: 12/19/2016] [Indexed: 01/13/2023]
Abstract
BACKGROUND There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease. The aim of the present study was to assess the safety and efficacy of a standard rapid desensitization protocol in patients with ASA sensitivity undergoing coronary angiography. METHODS AND RESULTS This is a prospective, multicenter, observational study including 7 Italian centers including patients with a history of ASA sensitivity undergoing coronary angiography with intent to undergo percutaneous coronary intervention. A total of 330 patients with history of ASA sensitivity with known/suspected stable coronary artery disease or presenting with an acute coronary syndrome, including ST-segment-elevation myocardial infarction were enrolled. Adverse effects to aspirin included urticaria (n=177, 53.6%), angioedema (n=69, 20.9%), asthma (n=65, 19.7%), and anaphylactic reaction (n=19, 5.8%). Among patients with urticaria/angioedema, 13 patients (3.9%) had a history of idiopathic chronic urticaria. All patients underwent a rapid ASA (5.5 hours) desensitization procedure. The desensitization procedure was performed before cardiac catheterization in all patients, except for those (n=78, 23.6%) presenting with ST-segment-elevation myocardial infarction who underwent the desensitization after primary percutaneous coronary intervention. Percutaneous coronary intervention was performed in 235 patients (71%) of the overall study population. The desensitization procedure was successful in 315 patients (95.4%) and in all patients with a history of anaphylactic reaction. Among the 15 patients (4.6%) who did not successfully respond to the desensitization protocol, adverse reactions were minor and responded to treatment with corticosteroids and antihistamines. Among patients with successful in-hospital ASA desensitization, 253 patients (80.3%) continued ASA for at least 12 months. Discontinuation of ASA in the 62 patients (19.7%) who had responded to the desensitization protocol was because of medical decision and not because of hypersensitivity reactions. CONCLUSIONS A standard rapid desensitization protocol is safe and effective across a broad spectrum of patients, irrespective of the type of aspirin sensitivity manifestation, with indications to undergo coronary angiography with intent to perform percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT02848339.
Collapse
|
86
|
Angelillis M, Giannini C, De Carlo M, Adamo M, Nardi M, Colombo A, Chieffo A, Bedogni F, Brambilla N, Tamburino C, Barbanti M, Bruschi G, Colombo P, Poli A, Martina P, Violini R, Presbitero P, Petronio AS. Prognostic Significance of Change in the Left Ventricular Ejection Fraction After Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis and Left Ventricular Dysfunction. Am J Cardiol 2017; 120:1639-1647. [PMID: 28844511 DOI: 10.1016/j.amjcard.2017.07.064] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Revised: 07/08/2017] [Accepted: 07/21/2017] [Indexed: 11/30/2022]
Abstract
Patients with severe aortic stenosis and reduced left ventricular ejection fraction (LVEF) have a poor prognosis compared with patients with preserved LVEF. To evaluate the impact of early LVEF recovery in patients with baseline dysfunction on clinical outcomes after transcatheter aortic valve implantation (TAVI), we included all consecutive patients who underwent TAVI from the Italian ClinicalService registry with an LVEF of ≤45% at baseline who had 1-month LVEF data. Patients who experienced a previous coronary artery bypass graft, a previous valve replacement, or a previous myocardial infarction were excluded from the analysis. Therefore, 131 patients with an improvement in LVEF of <10% (no-R group) were compared with 121 patients with an improvement in LVEF of ≥10% (R group). The primary end point was the rate of death of any cause. Multivariable analysis was performed to determine independent predictors of lack in LVEF recovery. Early LVEF recovery occurred in 48% of the patients, generally before discharge. One-year all-cause mortality and major adverse cardiac and cerebrovascular events were significantly higher in the no-early recovery group (log rank test p = 0.005 and p = 0.003, respectively). Baseline severe left ventricular dysfunction and previous percutaneous coronary intervention were identified as independent predictors to warn the lack of improvement in LVEF. In conclusion, nearly 50% of patients with preoperative left ventricular dysfunction demonstrated a significant early improvement in LVEF after TAVI. Lack of early LVEF recovery is associated with a worse clinical outcome and is most likely among patients with a severely abnormal baseline LVEF and a previous percutaneous coronary intervention.
Collapse
|
87
|
Bossi I, D'Anna M, Valentina V, Caria M, Canova P, Colombo P, Piccaluga E, Piccalo' G, Soriano F, Nava S, Oliva F. P519Predictors of target lesion revascularization after paclitaxel-coated balloon treatment of in-stent restenosis: a real-world single center registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
88
|
Stefanini G, Bruschi G, Cao D, Petronio A, Giannini C, Fiorina C, Adamo M, Colombo P, Latib A, Agnifili M, Poli A, Tamburino C, Fabbiocchi F, Giudice P, Reimers B. 1282Impact of antithrombotic strategies on clinical outcomes after self-expandable TAVI. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.1282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
89
|
Bossi I, Vaccaro V, D'Anna M, Canova P, Colombo P, Nava S, Piccaluga E, Piccalo G, Soriano F, Oliva F, Frigerio M. P6072The role of paclitaxel-coated balloons for the management of in-stent or in-scaffold restenosis in patients with allograft vasculopathy: results from a case series of consecutive patients. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
90
|
Giannini C, De Carlo M, Tamburino C, Ettori F, Latib AM, Bedogni F, Bruschi G, Presbitero P, Poli A, Fabbiocchi F, Violini R, Trani C, Giudice P, Barbanti M, Adamo M, Colombo P, Benincasa S, Agnifili M, Petronio AS. Transcathether aortic valve implantation with the new repositionable self-expandable Evolut R versus CoreValve system: A case-matched comparison. Int J Cardiol 2017; 243:126-131. [PMID: 28595747 DOI: 10.1016/j.ijcard.2017.05.095] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Revised: 04/05/2017] [Accepted: 05/25/2017] [Indexed: 10/19/2022]
Abstract
BACKGROUND Despite promising results following transcatheter aortic valve implantation (TAVI), several relevant challenges still remain. To overcome these issues, new generation devices have been developed. The purpose of the present study was to determine whether TAVI with the new self-expanding repositionable Evolut R offers potential benefits compared to the preceding CoreValve, using propensity matching. METHODS Between June 2007 and November 2015, 2148 consecutive patients undergoing TAVI either CoreValve (n=1846) or Evolut R (n=302) were prospectively included in the Italian TAVI ClinicalService® project. For the purpose of our analysis 211 patients treated with the Evolut R were matched to 211 patients treated with the CoreValve. An independent core laboratory reviewed all angiographic procedural data and an independent clinical events committee adjudicated all events. RESULTS Patients treated with Evolut R experienced higher 1-year overall survival (log rank test p=0.045) and a significantly lower incidence of major vascular access complications, bleeding events and acute kidney injury compared to patients treated with the CoreValve. Recapture manoeuvres to optimize valve deployment were performed 44 times, allowing a less implantation depth for the Evolut R. As a consequence, the rate of more than mild paravalvular leak and new permanent pacemaker was lower in patients receiving the Evolut R. CONCLUSION In this matched comparison of high surgical risk patients undergoing TAVI, the use of Evolut R was associated with a significant survival benefit at 1year compared with the CoreValve. This was driven by lower incidence of periprocedural complications and higher rates of correct anatomic positioning.
Collapse
|
91
|
Musumeci G, Faggiano P, Ferlini M, Lettieri C, Castiglioni B, Maggi A, Negri F, Colombo P, Oliva F, Pedretti RFE, Centola M, Rossini R. [Follow-up strategies after percutaneous coronary intervention: prognostic stratification and multidisciplinary management based on patient risk profile]. GIORNALE ITALIANO DI CARDIOLOGIA (2006) 2017; 18:3-12. [PMID: 28492563 DOI: 10.1714/2655.27229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The number of percutaneous coronary interventions (PCI) is increasing worldwide. Follow-up strategies after PCI are extremely heterogeneous and can greatly affect the cost of medical care. In the present paper, practical advises are provided with respect to a tailored follow-up strategy on the basis of patients' risk profile. Clinical and interventional cardiologists, cardiac rehabilitators, and general practitioners equally contributed to the creation of the present document and defined three follow-up strategies and types and timing of clinical and instrumental evaluations in post-PCI patients.
Collapse
|
92
|
Ascolese A, Navarria P, Mancosu P, Tomatis S, Fogliata A, Colombo P, De Sanctis R, Marrari A, Franceschini D, D'Agostino G, Santoro A, Quagliuolo V, Scorsetti M. EP-1375: Volumetric-modulated-arc-therapy versus 3D-conformal-radiotherapy for sarcoma of extremities. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31810-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
93
|
Adamo M, Bonmassari R, Bernardi G, Colombo P, Esposito G, Ferlini M, La Manna AG, Limbruno U, Marchese A, Mauro C, Menozzi A, Nicosia A, Rigattieri S, Tarantini G, Tarantino F, Valgimigli M, Varbella F, Musumeci G. [Bioequivalence and excipients: the case of tirofiban. A warning from the Italian Society of Interventional Cardiology (SICI-GISE)]. GIORNALE ITALIANO DI CARDIOLOGIA (2006) 2017; 18:35S-36S. [PMID: 28398400 DOI: 10.1714/2657.27247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
94
|
Bruschi G, Colombo P, Nava S, Musca F, Merlanti B, Belli O, Soriano F, Botta L, De Caria D, Giannattasio C, Russo CF. Evolut R Implantation to Treat Severe Pure Aortic Regurgitation in a Patient With Mitral Bioprosthesis. Ann Thorac Surg 2017; 102:e521-e524. [PMID: 27847071 DOI: 10.1016/j.athoracsur.2016.05.054] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Revised: 05/04/2016] [Accepted: 05/09/2016] [Indexed: 11/26/2022]
Abstract
Transcatheter aortic valves have been designed to treat high-risk surgical candidates affected by severe aortic stenosis, but little is known about the use of transcatheter valves in patients with severe pure aortic regurgitation. We describe the implantation of Medtronic CoreValve Evolut R (Medtronic, Minneapolis, MN) to treat an 82-year-old patient affected by severe pure aortic regurgitation who underwent prior mitral valve replacement with a biological valve protruding into the left ventricular outflow tract.
Collapse
|
95
|
Sridharan L, Givens R, Garan A, Yuzefpolskaya M, Takeda K, Takayama H, Latif F, Haythe J, Restaino S, Maurer M, Mancini D, Farr M, Naka Y, Colombo P, Topkara V. Mechanical Circulatory Support Devices (MSCD) Therapy in the Era of the Affordable Care Act (ACA): National Trends in Hospitalization Costs and In-Hospital Mortality. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.1433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
96
|
Fine B, Marx A, Topkara V, Gomez E, Vunjak-Novakovic G, Colombo P. An Integrated Analysis of Metabolomics After Left Ventricular Assist Device Implantation. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.235] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
97
|
Sridharan L, Givens R, Takeda K, Garan A, Yuzefpolskaya M, Latif F, Restaino S, Haythe J, Ginns J, Mancini D, Naka Y, Colombo P, Maurer M, Takayama H, Topkara V. The New Heart Allocation System: Implications on Patients with Restrictive Cardiomyopathy in the UNOS Registry. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
98
|
Habal M, Garan A, Topkara V, Takeda K, Latif F, Restaino S, Yuzefpolskaya M, Bijou R, Colombo P, Takayama H, Naka Y, Farr M. VA ECMO as a Bridge to Transplantation: Emergent Eligibility and Outcomes. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
99
|
Turazza F, Vaccaro V, Bossi I, D'Anna M, Piccalò G, Pedrazzini G, Masciocco G, Foti G, Colombo P, Perna E, Ammirati E, Frigerio M. Predictors of Clinical Outcome and Subsequent Target Lesion Revascularization After Percutaneous Coronary Procedures with Drug Eluting Stents and Everolimus Eluting Bioresorbable Scaffolds for Cardiac Allograft Vasculopathy. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
100
|
Fine B, Zorn E, Chen E, Vunjak-Novakovic G, Colombo P. Pre-Transplant Serum Exosome and Functional Analysis in Primary Graft Dysfunction. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|